Comparative Pharmacology
Head-to-head clinical analysis: KANTREX versus NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANTREX versus NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC.
KANTREX vs NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. Polymyxin B is a polypeptide that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan biosynthesis.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
Apply thin layer to affected area 2-3 times daily. For ophthalmic use: 1-2 drops in affected eye every 4 hours, or 1/2 inch ribbon of ointment in conjunctival sac 2-3 times daily.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Neomycin: 2-3 h (terminal), prolonged in renal impairment; polymyxin B: 6-7 h (terminal), extended in renal failure; bacitracin: 1.5 h (if absorbed), not clinically relevant due to minimal absorption.
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Renal: ~90% of absorbed neomycin and polymyxin B; bacitracin zinc: minimal systemic absorption, excreted primarily in feces. For neomycin: ~99% fecal after oral; polymyxin B: ~60% renal, rest biliary; bacitracin: nearly 100% renal if absorbed.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic